Pharmaceutical formulation

Focus on Customers Continues with Idaho Milk Products’ Episode 8 ‘How to Future-Proof R&D Formulations Using Sustainable and Clean Milk Protein and Milk Permeate’

Retrieved on: 
Tuesday, September 5, 2023
Cream, University of Colorado Denver School of Public Affairs, Common white wave, Union of Sales and Marketing Professionals, Milk protein concentrate, MPC, University, National Dairy Research Institute, Food industry, Pharmaceutical formulation, Marketing, MPP, Episode 8, Farmer, Acosta Sales & Marketing, Sunkesula Barrage, MPI, College of Applied Food and Dairy Technology, Cheese, History, Whey, Milk, Protein, Dairy, Nestlé, Drink, Research

Kevin Quinn joined Idaho Milk Products in December 2022 as Vice President of Sales and Marketing.

Key Points: 
  • Kevin Quinn joined Idaho Milk Products in December 2022 as Vice President of Sales and Marketing.
  • Kevin will be presenting the history of Idaho Milk Products.
  • D., joined Idaho Milk Products in July 2019 and is the VP of Research and Product Development.
  • If you want to view past webinars, visit https://www.idahomilkproducts.com/download-center / or talk to one of our sales managers at [email protected] .

Final Weeks to Register: 2 Day Pharmaceutical Regulatory Affairs in Asia Training Course - All Important Aspects of Gaining and Maintaining a Successful Marketing Authorisation (June 14-16, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, April 10, 2023
Health, Pharmaceutical, Allen & Hanburys, Active ingredient, Pharma, Pharmaceutical formulation, London Organising Committee of the Olympic and Paralympic Games, University of Basel, University of Strathclyde, Head, DRA, Editorial board, Foreign, Commonwealth and Development Office, GSK plc, Biochemistry, Publication, Pharmaceutics, University of Manchester, Roche, Textbook, WHO, Novartis, Pharmaceutical industry, Pharmacy, Medtech, Chemistry

Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.

Key Points: 
  • Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Focus on Customers Continues with Idaho Milk Products’ Episode 7 ‘Milk Protein Concentrate/Isolate Helps Create Excellent High-Protein Food Applications’

Retrieved on: 
Tuesday, March 14, 2023
Cream, Union of Sales and Marketing Professionals, Keebler Company, Change, Acosta Sales & Marketing, University of Colorado Engineering Management Program, Technical, University of Wisconsin–Madison, Investment company, MS, Milk, Protein, Master of Science, Food, Food industry, Food science, CDR, Pharmaceutical formulation, History, Pratishtha, KJ, Marketing, Common white wave, Snack, Episode 7, University, Dairy, Nestlé

Jerome, ID, March 14, 2023 (GLOBE NEWSWIRE) -- Idaho Milk Products will present Episode 7 in their Formulating with Milk Proteins webinar series on ‘Milk Protein Concentrate/Isolate Helps Create Excellent High-Protein Food Applications’.

Key Points: 
  • Jerome, ID, March 14, 2023 (GLOBE NEWSWIRE) -- Idaho Milk Products will present Episode 7 in their Formulating with Milk Proteins webinar series on ‘Milk Protein Concentrate/Isolate Helps Create Excellent High-Protein Food Applications’.
  • Speakers will include Kevin Quinn, Vice President of Sales & Marketing at Idaho Milk Products, Kimberlee (KJ) Burrington, VP of Technical Development with American Dairy Products Institute (ADPI) and Pratishtha Verma, MSc, Research & Development Scientist at Idaho Milk Products.
  • Mr. Quinn came to Idaho Milk Products in December 2022 as Vice President of Sales and Marketing.
  • Pratishtha will cover understanding the opportunities and challenges of using MPI/MPCs in food and walk through real-time applications using Idaho Milk Products’ milk protein product range.

Pharmaceutical Regulatory Affairs in China Training Course (April 17-18, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, March 13, 2023
Health, Pharmaceutical, University of Strathclyde, Novartis, Pharmaceutical formulation, Publication, WHO, Roche, DRA, Head, University of Basel, Biochemistry, Textbook, Editorial board, Foreign, Commonwealth and Development Office, London Organising Committee of the Olympic and Paralympic Games, Pharma, GSK plc, Active ingredient, Pharmaceutics, Allen & Hanburys, University of Manchester, Pharmaceutical industry, Chemistry, Pharmacy, Medtech

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.

2 Day Pharmaceutical Regulatory Affairs in China Training Course: Maintain a Successful Pharmaceutical Marketing Authorisation in PRC, including Hong Kong, Macau and Taiwan (April 17-18, 2023)

Retrieved on: 
Saturday, March 11, 2023
WHO, Pharma, DRA, Head, University of Strathclyde, Active ingredient, GSK plc, Editorial board, Foreign, Commonwealth and Development Office, Allen & Hanburys, Textbook, University of Basel, Pharmaceutical formulation, Pharmaceutics, London Organising Committee of the Olympic and Paralympic Games, Biochemistry, Roche, Novartis, University of Manchester, Publication, Pharmaceutical industry, Chemistry, Pharmacy, Medtech

Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.

Key Points: 
  • Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Asia Pharmaceutical Regulatory Affairs Training Course: Opportunities and Challenges to those Wishing to Work in the Region (October 11-13, 2023)

Retrieved on: 
Wednesday, March 1, 2023
Pharmaceutics, Allen & Hanburys, Active ingredient, GSK plc, Foreign, Commonwealth and Development Office, Roche, DRA, University of Basel, Publication, Pharma, Head, WHO, London Organising Committee of the Olympic and Paralympic Games, Pharmaceutical formulation, University of Strathclyde, University of Manchester, Textbook, Biochemistry, Editorial board, Novartis, Pharmaceutical industry, Medtech, Pharmacy, Chemistry

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Asia Pharmaceutical Regulatory Affairs Training Course: Opportunities and Challenges to those Wishing to Work in the Region (October 11-13, 2023) - ResearchAndMarkets.com

Retrieved on: 
Friday, February 24, 2023
Pharmaceutical, Legal, Professional Services, Health, Pharmaceutics, Allen & Hanburys, Active ingredient, GSK plc, Foreign, Commonwealth and Development Office, Roche, DRA, University of Basel, Publication, Pharma, Head, WHO, London Organising Committee of the Olympic and Paralympic Games, Pharmaceutical formulation, University of Strathclyde, University of Manchester, Textbook, Biochemistry, Editorial board, Novartis, Pharmaceutical industry, Medtech, Pharmacy, Chemistry

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

New Job Sequencing Enabled by Treadstone® Underlayments

Retrieved on: 
Tuesday, January 17, 2023
Chills, General contractor, Marketing, Pharmaceutical formulation, Water, Risk, Plaster

A pairing of two products to save time, money and improve building safety is a perfect example of this."

Key Points: 
  • A pairing of two products to save time, money and improve building safety is a perfect example of this."
  • This impressive strength allows multi-family construction projects to be sequenced allowing for measurable savings in time and money to the General Contractors.
  • Without walls in place, crews can pour the gypsum cement faster with better leveling which benefits other trades like drywall and flooring.
  • Furthermore, elimination of many of the prep steps ensures that jobs run quicker and more efficient than the previous method of installation.

Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Degenerative disease, Target, History, Sleep, Discovery, Diabetes, Risk, Metabolism, Mall of America, R, News, Medication, Health, Therapy, Pharmaceutical formulation, Research, Drug, Pharmaceutical industry, Medical device, Surveying, Oil, Marketing, Obesity

Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2022, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Obesity - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.
  • - The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Target, Psoriasis, History, Risk factor, Psoriatic arthritis, The, Discovery, Low back pain, Mall of America, R, News, Medication, Human musculoskeletal system, Finger, Therapy, Nonsteroidal anti-inflammatory drug, Pharmaceutical formulation, Arthritis, Research, Pharmaceutical industry, Medical device, Surveying, Oil, Marketing

Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.
  • - The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.